BK Virus Infection (BKV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

BK Virus Infection (BKV) Market Outlook

Thelansis’s “BK Virus Infection (BKV) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential BK Virus Infection (BKV) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

BK Virus Infection (BKV) Overview

BK polyomavirus (BKV) belongs to the Polyomaviridae family of double-stranded DNA (dsDNA) viruses. BKV is a common childhood infection that rarely leads to severe clinical consequences, and over 80% of adults have antibodies against BKV. BKV remains latent after the primary infection in healthy individuals and does not cause significant morbidity. However, in some immunosuppressed individuals, such as those with HIV infection or who have undergone transplantation, BKV may reactivate and cause clinical complications. Among these patients, kidney transplant recipients (KTRs) are the most commonly affected, with a median of 19.5% developing BK viremia after transplantation. BKV enters the bloodstream through infected tonsillar tissue, infecting peripheral blood mononuclear cells and spreading to secondary sites of infection, such as the kidney. BKV DNA has been detected in leukocytes, lymph nodes, and the brain. The mechanisms underlying viral persistence and reactivation upon immunosuppression remain unclear. The major clinical manifestations of BKV infection are BKV-associated nephropathy (BKVAN) or ureteric stenosis in KTRs and hemorrhagic cystitis, mostly seen in hematopoietic stem cell transplant (HSCT) recipients. Other less common clinical manifestations of BKV infection include interstitial pneumonitis and meningoencephalitis. Donor BKV seropositivity and recipient BKV seronegativity increase the risk of developing BKVAN and graft rejection, with a tenfold higher risk of BK viremia in KTRs when the donor is seropositive, and the recipient is seronegative, compared to cases where both are seronegative.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: BK Virus Infection (BKV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034